Product Name: Ivabradine hydrochloride
Synonyms: 3-[3-[[[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one Hydrochloride;Corlentor;Procoralan;S-16257;(7,8-Dimethoxy 3-(3-(((1S)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one hydrochloride;2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, monohydrochloride;2H-3-Benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, monohydrochloride, (S)-;Ivabridine hydracloride
CAS: 148849-67-6
MF: C27H36N2O5.HCl
MW: 505.05
EINECS: 638-798-3
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;API;Chiral Reagents;Heterocycles;Cardiovascular APIs;Inhibitors
Mol File: 148849-67-6.mol

Ivabradine hydrochloride Chemical Properties
Melting point  193-196 C
alpha  58921 +7.8°; 36521 +27.8° (c = 1% in DMSO)
storage temp.  -20°C Freezer
solubility  H2O: ≥5mg/mL (warmed)
form  powder
color  white to beige
optical activity [α]/D +5 to +9°, c = 1 in DMSO
Merck  14,5247
InChIKey HLUKNZUABFFNQS-ZMBIFBSDSA-N
CAS DataBase Reference 148849-67-6(CAS DataBase Reference)
Safety Information
Hazard Codes  N
Risk Statements  50/53
Safety Statements  60-61
RIDADR  UN 3077 9 / PGIII
WGK Germany  3

Ivabradine hydrochloride Usage And Synthesis
Description In an effort to develop angina agents without the unwanted negative inotropic and hypotensive effects associated with b-adrenergic blockers and calcium channel blockers, a new class of heart-rate reducing compounds that act specifically on the sinoatrial (SA) node has been explored. These bradycardic agents interact directly with the pacemaking cell of the SA node and the hyperpolarization- activated If , the primary pacemaking current. Ivabradine has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease. Using a patch-clamp technique on rabbit sinoatrial node cells, inhibition of If current ranged from 6% (0.03 mM) – 80% (10 mM). .

Product Name: Ivabradine hydrochloride
Synonyms: 3-[3-[[[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one Hydrochloride;Corlentor;Procoralan;S-16257;(7,8-Dimethoxy 3-(3-(((1S)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one hydrochloride;2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, monohydrochloride;2H-3-Benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, monohydrochloride, (S)-;Ivabridine hydracloride
CAS: 148849-67-6
MF: C27H36N2O5.HCl
MW: 505.05
EINECS: 638-798-3
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;API;Chiral Reagents;Heterocycles;Cardiovascular APIs;Inhibitors
Mol File: 148849-67-6.mol

Ivabradine hydrochloride Chemical Properties
Melting point  193-196C
alpha  58921 +7.8°; 36521 +27.8° (c = 1% in DMSO)
storage temp.  -20°C Freezer
solubility  H2O: ≥5mg/mL (warmed)
form  powder
color  white to beige
optical activity [α]/D +5 to +9°, c = 1 in DMSO
Merck  14,5247
InChIKey HLUKNZUABFFNQS-ZMBIFBSDSA-N
CAS DataBase Reference 148849-67-6(CAS DataBase Reference)
Safety Information
Hazard Codes  N
Risk Statements  50/53
Safety Statements  60-61
RIDADR  UN 3077 9 / PGIII
WGK Germany  3

Ivabradine hydrochloride Usage And Synthesis
Description In an effort to develop angina agents without the unwanted negative inotropic and hypotensive effects associated with b-adrenergic blockers and calcium channel blockers, a new class of heart-rate reducing compounds that act specifically on the sinoatrial (SA) node has been explored. These bradycardic agents interact directly with the pacemaking cell of the SA node and the hyperpolarization- activated If , the primary pacemaking current. Ivabradine has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease. Using a patch-clamp technique on rabbit sinoatrial node cells, inhibition of If current ranged from 6% (0.03 mM) – 80% (10 mM). .